Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Garfall, Alfred L.
Nooka, Ajay K.
van de Donk, Niels W. C. J.
Moreau, Philippe
Bhutani, Manisha
Oriol, Albert
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita Y.
Delforge, Michel
Huang, Lin
Vishwamitra, Deeksha
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
机构：
[1] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[3] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[4] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France
[5] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[6] Hosp Badalona Germans Trias & Pujol, Inst Catal Oncol, Badalona, Spain
[7] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[8] Univ Calif San Francisco, San Francisco, CA USA
[9] IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain
[10] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Centro Invest Canc IBMCC USAL, CSIC, Salamanca, Spain
[11] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[12] Univ Coll London Hosp, NHS Fdn Trust, London, England
[13] Univ Hosp Tubingen, Tubingen, Germany
[14] Hosp 12 Octubre, Hematol, Madrid, Spain
[15] City Hope Comprehens Canc Ctr, Duarte, CA USA
[16] Univ Leuven, Leuven, Belgium
[17] Johnson & Johnson Innovat Med, Spring House, PA USA
[18] Johnson & Johnson Innovat Med, Raritan, NJ USA
[19] Stanford Univ, Sch Med, Stanford, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7540
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Clinical Outcomes of Teclistamab among MajesTEC-1 Eligible and Ineligible Population in the Real-World Setting for the Treatment of Relapsed/Refractory Multiple Myeloma
    Tan, Carlyn
    Derkach, Andriy
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Rajeeve, Sridevi
    Hashmi, Hamza
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio
    Lesokhin, Alexander
    Korde, Neha
    Lin, Dee
    Wu, Bingcao
    Fowler, Jessica
    Fernandez, Mariana
    Kim, Nina
    Doyle, Margaret
    Hester, Laura
    Orozco, Jennifer
    Usmani, Saad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S91 - S92
  • [32] Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician's choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
    Mateos, Maria-Victoria
    Chari, Ajai
    Usmani, Saad Zafar
    Goldschmidt, Hartmut
    Weisel, Katja
    Qi, Keqin
    Londhe, Anil
    Nair, Sandhya
    Lin, Xiwu
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok V.
    Slavcev, Mary
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Usmani, Saad Z.
    Garfall, Alfred L.
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas
    Rosino, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar J.
    Popat, Rakesh
    Besemer, Britta
    Martínez-López, Joaquín
    Sidana, Surbhi
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca I.
    Girgis, Suzette
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa M.
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita Y.
    BLOOD, 2021, 138
  • [34] Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study (vol 130, pg 886, 2024)
    Nooka, A. K.
    Rodriguez, C.
    Mateos, M., V
    CANCER, 2024, 130 (17) : 3046 - 3046
  • [35] LENALIDOMIDE LONG-TERM NEUROTOXICITY: NEUROPHYSIOLOGICAL FOLLOW-UP STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MYELOMA
    Dalla Torre, C.
    Cacciavillani, M.
    Campagnolo, M.
    Lucchetta, M.
    Bemo, T.
    De March, E.
    Zambello, R.
    Briani, C.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2015, 20 (02) : 122 - 122
  • [36] Updated long-term follow-up results of a phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with equecabtagene autoleucel
    Li, Chunrui
    Wang, Di
    Fang, Baijun
    Huang, He
    Li, Jianyong
    Chen, Bing
    Liu, Jing
    Ren, Hanyun
    Dong, Yujun
    Hu, Kai
    Liu, Peng
    Zhang, Xi
    Mi, Jian-Qing
    Li, Zhenyu
    Ding, Kaiyang
    Cai, Song-Bai
    Gui, Hong-Yu
    Wang, Wen
    Qiu, Lugui
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S196 - S197
  • [37] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
    Cortes-Selva, Diana
    Casneuf, Tineke
    Vishwamitra, Deeksha
    Stein, Sarah
    Perova, Tatiana
    Skerget, Sheri
    Ramos, Elena
    van Steenbergen, Laure
    De Maeyer, Dries
    Boominathan, Rengasamy
    Lau, Onsay
    Davis, Cuc
    Banerjee, Arnob
    Stephenson, Tara
    Uhlar, Clarissa M.
    Kobos, Rachel
    Goldberg, Jenna D.
    Pei, Lixia
    Trancucci, Danielle
    Girgis, Suzette
    Lin, Shun Xin Wang
    Wu, Liviawati S.
    Moreau, Philippe
    Usmani, Saad
    Bahlis, Nizar Jacques
    Van de Donk, Niels W. C. J.
    Verona, Raluca
    BLOOD, 2022, 140
  • [38] Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
    Jin, Chunxiang
    Chen, Rongrong
    Fu, Shan
    Zhang, Mingming
    Teng, Yuanyin
    Yang, Tingting
    Song, Fengmei
    Feng, Jingjing
    Hong, Ruimin
    Cui, Jiazhen
    Huang, Simao
    Xu, Huijun
    Zhang, Yanlei
    Wei, Guoqing
    Cai, Zhen
    Kwong, Yok-Lam
    Chan, Thomas Sau Yan
    Chang, Alex H.
    Huang, He
    Hu, Yongxian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (03)
  • [39] Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
    Usmani, Saad Z.
    Garfall, Alfred L.
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Karlin, Lionel
    Benboubker, Lotfi
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Elsayed, Yusri
    Infante, Jeffrey
    Goldberg, Jenna D.
    Banerjee, Arnob
    Mateos, Maria-Victoria
    Krishnan, Amrita
    LANCET, 2021, 398 (10301): : 665 - 674
  • [40] Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1
    Bringhen, Sara
    Voorhees, Peter M.
    Plesner, Torben
    Mellqvist, Ulf-Henrik
    Reeves, Brandi
    Sonneveld, Pieter
    Byrne, Catriona
    Nordstrom, Eva
    Harmenberg, Johan
    Obermuller, Jakob
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (06) : 1105 - 1109
12345